Is BRAF the Achilles' Heel of Thyroid Cancer?
Open Access
- 15 March 2006
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (6), 1661-1664
- https://doi.org/10.1158/1078-0432.ccr-06-0051
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Inhibitors of Raf Kinase Activity Block Growth of Thyroid Cancer Cells with RET/PTC or BRAF Mutations In vitro and In vivoClinical Cancer Research, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Mutations of C-RAF Are Rare in Human Cancer because C-RAF Has a Low Basal Kinase Activity Compared with B-RAFCancer Research, 2005
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005
- The RAF proteins take centre stageNature Reviews Molecular Cell Biology, 2004
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- B-RAF is a therapeutic target in melanomaOncogene, 2004
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAFCell, 2004
- Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumorsOncogene, 1999
- The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patientsJournal of Clinical Endocrinology & Metabolism, 1992